Reverie Labs
Latest round
- Series A
Last raised
- Feb 2021
Total raised
- $25M
Investors
- 9
About Reverie Labs
Based in Massachusetts, US, and founded in 2017, Reverie Labs, which operates as a pharmaceutical company develops deep learning-based modeling, massive-scale computation, and genetic algorithms to engineer new medicines. The company operates a drug discovery platform that uses computational chemistry and machine learning-technology to discover and develop kinase inhibitors. As of 2024, the company's product line has cancer-treating drugs such as RVL-101, RVL-1-2, and RVL-103, which are developed by partnering with other organizations such as Roche and Genentech
Who invested in Reverie Labs
9 investors across 2 rounds
See all investors in Reverie Labs
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Reverie Labs
Who invested in Reverie Labs?
Reverie Labs has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reverie Labs raised?
Reverie Labs has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Reverie Labs last raise money?
Reverie Labs's most recent round on record is a Series A, in Feb 2021.
What does Reverie Labs do?
Based in Massachusetts, US, and founded in 2017, Reverie Labs, which operates as a pharmaceutical company develops deep learning-based modeling, massive-scale computation, and genetic algorithms to engineer new medicines.
Where is Reverie Labs headquartered?
Reverie Labs is headquartered in Cambridge, US.
Which VCs invest in companies like Reverie Labs?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Reverie Labs's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Reverie Labs? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.